ArticleFrontiers in oncology2025
MiR-10a-5p suppresses hepatocellular carcinoma progression and microvascular invasion by targeting TFR1-STAT3-CD24 signaling axis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Spatiotemporal Heterogeneity of oncomiRNAs: A New Frontier in Cancer Therapy.Cancer reports (Hoboken, N.J.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preoperative CT features have demonstrated potential in predicting microvascular invasion (MVI) in hepatocellular carcinoma. These CT signs serve as indicators of tumor biological behavior. However, the molecular mechanisms underlying the ability of CT to preoperatively predict MVI remain largely unexplored. This study aims to elucidate the role of miR-10a-5p in HCC progression and investigate its correlation with specific imaging features. Methods: According to preoperative CT features, patients were divided into CT-MVI (+) group and CT-MVI (-) group. MiR-10a-5p expression was analyzed in HCC tissues with CT-MVI compared to those without CT-MVI. The functional effects of miR-10a-5p were assessed through Results: MiR-10a-5p expression was significantly downregulated in HCC tissues with CT-MVI compared to those without CT-MVI. Overexpression of miR-10a-5p reduced cell viability, promoted apoptosis, and inhibited tumor growth Conclusions: Our findings reveal miR-10a-5p as a key regulator of HCC progression and MVI, operating through a novel pathway involving TFR1, STAT3, and CD24. This study provides new insights into the molecular mechanisms of CT features and highlights potential therapeutic targets for HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.